• This record comes from PubMed

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

. 2016 Jan ; 51 (1) : 51-7. [epub] 20150914

Language English Country Great Britain, England Media print-electronic

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid26367239

Grant support
15556 Cancer Research UK - United Kingdom
P30 CA008748 NCI NIH HHS - United States

Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.

Comment In

PubMed

See more in PubMed

Biol Blood Marrow Transplant. 2014 Nov;20(11):1667-9 PubMed

Haematologica. 2013 Oct;98(10):1554-62 PubMed

J Clin Oncol. 1999 Apr;17(4):1244 PubMed

Blood. 2004 Jan 1;103(1):275-82 PubMed

J Clin Oncol. 2010 Sep 20;28(27):4184-90 PubMed

J Clin Oncol. 2011 Apr 1;29(10):1342-8 PubMed

Onco Targets Ther. 2013 Mar 31;6:289-96 PubMed

J Clin Oncol. 2014 Nov 1;32(31):3472-3 PubMed

Lancet Oncol. 2014 Jun;15(7):757-66 PubMed

N Engl J Med. 1995 Dec 7;333(23):1540-5 PubMed

J Clin Oncol. 2013 Aug 10;31(23):2912-9 PubMed

J Clin Oncol. 2012 Dec 20;30(36):4462-9 PubMed

Biol Blood Marrow Transplant. 2012 May;18(5):788-93 PubMed

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2349-54 PubMed

J Clin Oncol. 2011 Nov 1;29(31):4079-87 PubMed

Adv Hematol. 2012;2012:195484 PubMed

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36 PubMed

Blood. 2013 Jul 25;122(4):499-506 PubMed

Blood. 2010 Sep 23;116(12):2040-5 PubMed

Hematology Am Soc Hematol Educ Program. 2012;2012:410-6 PubMed

Blood. 2008 Jan 15;111(2):537-43 PubMed

Leuk Lymphoma. 2007 Jul;48(7):1332-7 PubMed

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):192-6 PubMed

Hematology. 2008 Oct;13(5):261-6 PubMed

Lancet Oncol. 2014 Aug;15(9):1019-26 PubMed

Biol Blood Marrow Transplant. 2013 May;19(5):746-53 PubMed

Blood. 2002 Dec 15;100(13):4310-6 PubMed

Bone Marrow Transplant. 2014 Mar;49(3):361-5 PubMed

Am J Hematol. 2013 Oct;88(10):890-4 PubMed

Br J Haematol. 2005 Aug;130(3):363-72 PubMed

J Clin Oncol. 2014 Nov 1;32(31):3490-6 PubMed

Find record

Citation metrics

Archiving options